HUTCHMED Initiates Phase II Registration Study of HMPL-689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in China

NEXT STORY
ERYTECH Announces $30.0 Million Registered Direct Offering
PREV STORY
Valneva Announces Launch of Proposed Global Offering, Start of the Roadshow and Nasdaq Listing
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Revolo Biotherapeutics Activates Clinical Sites and Opens Enrollment in a Phase 2 Clinical Trial of ‘1104 in Eosinophilic Esophagitis

author_avatar
NASDAQ Market News

Novan Receives Approval to Transfer to Nasdaq Capital Market

author_avatar
NASDAQ Market News

Co-administration of AAV Vectors with SVP-Rapamycin Enables Vector Re-administration in Pre-clinical Gene Therapy Study Published in Nature Communications by Généthon and Selecta Biosciences

Represents a potentially powerful strategy to modulate vector immunogenicity and may open new therapeutic ...

author_avatar
NASDAQ Market News